

2-12-2015

# No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil

WL Marshall

*Merck & Co., Inc., Kenilworth, NJ, USA*

C. Badshah

*Merck & Co., Inc., Kenilworth, NJ, USA*

F. Liu

*Merck & Co., Inc., Kenilworth, NJ, USA*

Walter K. Kraft, MD

*Thomas Jefferson University, Philadelphia, USA, walter.kraft@jefferson.edu*

F. Colon-Gonzalez

*Merck & Co., Inc., Kenilworth, NJ, USA*

*See next page for additional authors*

[Let us know how access to this document benefits you](#)

Follow this and additional works at: <https://jdc.jefferson.edu/petfp>

 Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

## Recommended Citation

Marshall, WL; Badshah, C.; Liu, F.; Kraft, MD, Walter K.; Colon-Gonzalez, F.; Schanke, A. van; Cho, CR.; Hulskotte, E.; Butterson, JR; and Marcantonio, EE, "No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil" (2015). *Department of Pharmacology and Experimental Therapeutics Faculty Papers*. Paper 61.

<https://jdc.jefferson.edu/petfp/61>

---

**Authors**

WL Marshall; C. Badshah; F. Liu; Walter K. Kraft, MD; F. Colon-Gonzalez; A. van Schanke; CR. Cho; E. Hulskotte; JR Butterson; and EE Marcantonio

# No Evidence of a Drug-Drug Interaction Between Letemovir (MK-8228) and Mycophenolate Mofetil

WL Marshall<sup>1</sup>, C Badshah<sup>1</sup>, F Liu<sup>1</sup>, WK Kraft<sup>2</sup>, F Colon-Gonzalez<sup>1</sup>, A van Schanke<sup>3</sup>, J Udo de Haes<sup>4</sup>, B Kantesaria<sup>1</sup>, CR Cho<sup>1</sup>, E Hulskotte<sup>5</sup>, JR Butterson<sup>1</sup>, EE Marcantonio<sup>1</sup>

<sup>1</sup>Merck & Co., Inc., Kenilworth, NJ, USA; <sup>2</sup>Thomas Jefferson University, Philadelphia, PA, USA; <sup>3</sup>Quantitative Solutions B.V., Oss, The Netherlands; <sup>4</sup>PRA Health Sciences, Zuidlaren, The Netherlands;

<sup>5</sup>Astellas Pharma, Leiden, The Netherlands



## Abstract

**Introduction:** Letemovir (MK-8228) is a potent, once-daily inhibitor of the cytomegalovirus (CMV) terminase complex that is being developed for the prophylaxis of CMV infection in transplant patients. This study evaluated the pharmacokinetic interactions, safety, and tolerability of letemovir when coadministered in healthy subjects with mycophenolate mofetil (MMF), which is the morpholinoethyl ester prodrug of mycophenolic acid (MPA).

**Methods:** This was an open-label trial in 14 healthy female subjects that explored the pharmacokinetic parameters of a single 1 g oral dose of MMF administered alone on Day 1 and coadministered on Day 12 with 480 mg oral once-daily letemovir given on Day 5 and from Day 8 continued through Day 16. Letemovir PK was assessed at single dose (Day 5) and at steady state on Day 12 (with MMF) and Day 16 (alone following MMF washout).

**Results:** Coadministration of 480 mg qd letemovir at steady state with a single dose of 1 g of MMF had no effect on the pharmacokinetics of MPA. The MPA  $AUC_{0-24}$  and  $C_{max}$  geometric mean ratios (GMRs) [90% confidence interval] for the comparison (MMF with letemovir/MMF alone) were 1.08 [0.96, 1.21] and 0.96 [0.81, 1.13], respectively. Coadministration of a single dose of 1 g MMF with 480 mg qd letemovir at steady state had no clinically meaningful effect on the pharmacokinetics of letemovir, with  $AUC_{0-24}$  and  $C_{max}$  GMR of 1.18 [1.04, 1.32] and 1.11 [0.93, 1.34], respectively. The letemovir geometric mean accumulation ratio (Day 16/Day 5) and 95% CI were 1.13 [0.90, 1.42] for  $AUC_{0-24}$  and 1.01 [0.79, 1.28] for  $C_{max}$ , indicating that accumulation of letemovir when administered as daily doses is minimal. All related AEs were reported as mild in severity and resolved.

**Conclusions:** Multiple-dose administration of 480 mg letemovir daily with a single dose of 1 g MMF was generally well tolerated by the healthy subjects in this study. Coadministration of letemovir and MMF had no clinically meaningful effect on the PK of letemovir or MPA. Letemovir and MMF may be coadministered without dose adjustment.

## Background

Letemovir (MK-8228) belongs to a new class (terminase inhibitors) of anticytomegalovirus (CMV) agents and is a once-daily inhibitor in development to prevent CMV infection and disease in transplant patients

Mycophenolate mofetil (MMF) is indicated for prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants and is likely to be used as comedication in transplant patients

Mycophenolic acid (MPA), the active metabolite of MMF, is metabolized by several glucuronyl transferases (UGT1A7/8/9/10 and UGT2B7), CYP3A4/5, and CYP2C8 and is a substrate of the transporters OATP1B1 and 1B3 and the P-glycoprotein (P-gp). Letemovir is an inhibitor of CYP3A4 and CYP2C8 as well as OATP1B1, OATP1B3, and possibly P-gp. Thus, concentrations of MPA may potentially increase with letemovir coadministration

This trial investigated the potential effect of letemovir on MPA pharmacokinetics and also explored potential effects of MMF/MPA on letemovir pharmacokinetics

## Aims

To determine the effect of letemovir at steady state on the pharmacokinetic parameters of MPA following coadministration of a single dose of MMF to healthy female subjects. PK parameters included  $AUC_{0-inf}$ ,  $C_{max}$ ,  $T_{max}$ , and apparent terminal  $t_{1/2}$

To determine the effect of a single dose of MMF on the steady-state pharmacokinetic parameters of letemovir in healthy female subjects. Parameters included  $AUC_{0-24}$ ,  $C_{max}$ ,  $T_{max}$ , and apparent terminal  $t_{1/2}$

## Subject Demographics

All 14 subjects enrolled in this trial were female subjects between the ages of 20 and 49 years at screening with a body mass index (BMI) of 20.1 to 31.9 kg/m<sup>2</sup>. The mean age of subjects was 32.3 years. In total, 10 subjects (71.4%) were black or African American and 4 (28.6%) were white. (\*) One of the subjects who reported her race as black or African American also reported being of American Indian or Alaska Native descent (Table 1).

Table 1. Subject Characteristics

	Number of Subjects N=14 n (%)
Female	14 (100.0)
Age (yr)	32.3
Range	20 to 49
BMI (kg/m <sup>2</sup> ), range	20.1 to 31.9
Race	
Black or African American	10* (71.4)
White	4 (28.6)


## Safety and Tolerability

- Oral administration of 480 mg letemovir once daily was reasonably well tolerated by the healthy female subjects
- Drug-related AEs all belonged to the Gastrointestinal Disorders System Organ Class (8 subjects, 57.1%), except for one event of fatigue. All drug-related AEs were mild in intensity and were transient
- The events of diarrhea (3 subjects; 21.4%) were all single events. Two subjects (14.3%) reported single events of abdominal pain starting 45 minutes to ~2 hours after dosing on Days 13 (concomitant with nausea) and 16 (concomitant with diarrhea), respectively, with a duration of less than 3 hours. Vomiting occurred in one subject (7.1%) on a single occasion (Day 11, ~30 minutes after dosing, duration <1 min). Nausea was reported by 6 subjects (42.9%) on one or more occasions between Day 5 and Day 15
- Most gastrointestinal AEs occurred relatively shortly after dosing and were transient

## Letemovir (MK-8228) Pharmacokinetics

- A mean concentration profile of 480 mg letemovir (MK-8228) alone was compared to the mean concentration profile of 480 mg letemovir (MK-8228) when MMF was coadministered (Figure 2)
- The mean letemovir plasma concentration-time profile reached its peak at 2 hours postdose on Days 5, 12, and 16. All subjects had quantifiable plasma letemovir concentrations at the last time point drawn: 24 hours postdose on Day 12 and 72 hours postdose on Days 5 and 16. Mean trough concentrations ranged from 583 to 803 ng/mL, with %CV ranging from 43.1 to 67.2
- Summary statistical comparison of PK parameters from subjects administered 480 mg letemovir (MK-8228) alone compared to 480 mg letemovir (MK-8228) when MMF is coadministered in Table 2

Figure 2 (A) Mean letemovir concentration (linear scale) vs time by treatment group (letemovir single dose on Day 5, letemovir multiple dose + MMF single dose on Day 12, and letemovir multiple dose on Day 16); Figure 2B (semi-log scale)



## Results

Table 2. Letemovir pharmacokinetics post-480 mg multiple dosing alone (Day 16) or coadministered with a single dose of 1 g MMF (Day 12)

MPA-PK Parameter	MMF + Letemovir N=14		Letemovir Alone N=14		MMF + Letemovir vs Letemovir Alone		Pseudo Within Subject %CV
	Geometric Mean	95% CI	Geometric Mean	95% CI	GMR	90% CI	
$AUC_{0-24}$ (hr*ng/mL)	84,011	(61,722, 114,351)	71,482	(55,593, 91,911)	1.18	(1.04, 1.32)	4.74
$C_{max}$ (ng/mL)	14,497	(10,748, 19,553)	13,018	(10,721, 15,807)	1.11	(0.93, 1.34)	7.42
$T_{max}$ (hr)	2.0	(1.0, 3.0)	2.2	(1.0, 3.0)	--	--	--
$T_{1/2}$ (hr)	--	--	13.8	44.3	--	--	--

CI=confidence interval, PK=pharmacokinetics, CV=coefficient of variance, GMR=geometric least-squares mean ratio between treatments, MPA=mycophenolic acid, MMF=mycophenolate mofetil.

Back-transformed least-squares mean and CI was from linear mixed-effects model performed on natural log-transformed values.

Pseudo within-subject %CV =  $100 \cdot \sqrt{(\sigma_e^2 + \sigma_{AB}^2 - 2 \cdot \sigma_{AB})/2}$ , where  $\sigma_e^2$  and  $\sigma_{AB}^2$  are the estimated variances on the log scale for the 2 treatment groups and  $\sigma_{AB}$  is the corresponding estimated covariance, each obtained from the linear mixed-effects model.

## MPA Pharmacokinetics

- Figure 3A presents the mean MPA concentration (linear scale) vs time plots with data separated by treatment (MMF single dose on Day 1 and MMF single dose + letemovir multiple dose on Day 12) in the pharmacokinetic population. Figure 3B presents these data on a semi-log scale for MPA
- All subjects had no quantifiable predose concentrations of MPA on Day 1. The mean MPA plasma concentration-time profile reached its peak at 0.5 hours postdose on Days 1 and 12. All subjects had quantifiable plasma MPA concentrations up to 36 hours postdose on both Day 1 and Day 12

Table 3. Summary of pharmacokinetic parameters of mycophenolic acid (MPA) following single-dose administration of 1 g mycophenolate mofetil (MMF) (Day 1) alone or with 480 mg letemovir dosed to steady state (Day 12)

MPA PK Paramete	MMF + Letemovir N=14		MMF Alone N=14		MMF + Letemovir/ MMF Alone		Pseudo Within Subject %CV
	Geometric Mean	95% CI	Geometric Mean	95% CI	GMR	90% CI	
$AUC_{0-24}$ (hr*ng/mL)	68,131	(58,187, 79,775)	63,108	(53,152, 74,928)	1.08	(96.8, 120.4)	4.36
$C_{max}$ (ng/mL)	22,881	(18,520, 28,268)	23,858	(19,489, 29,207)	0.95	(81.9, 112.3)	6.29
$T_{max}$ (hr)	0.52	(0.5, 2.0)	0.52	(0.5, 2.0)	--	--	--
$T_{1/2}$ (hr)	13.1	42.6	13.3	27.2	--	--	--

CI=confidence interval, PK=pharmacokinetics, CV=coefficient of variance, GMR=geometric least-squares mean ratio between treatments, MPA=mycophenolic acid, MMF=mycophenolate mofetil.

Back-transformed least-squares mean and CI was from linear mixed-effects model performed on natural log-transformed values.

Pseudo within-subject %CV =  $100 \cdot \sqrt{(\sigma_e^2 + \sigma_{AB}^2 - 2 \cdot \sigma_{AB})/2}$ , where  $\sigma_e^2$  and  $\sigma_{AB}^2$  are the estimated variances on the log scale for the 2 treatment groups and  $\sigma_{AB}$  is the corresponding estimated covariance, each obtained from the linear mixed-effects model.

Figure 3 (A) Mean MPA concentration (linear scale) vs time plots with data separated by treatment (MMF single dose on Day 1 and MMF single dose + letemovir multiple dose on Day 12) (B) Semi-log scale




Table 4. Accumulation (GMR%) and time linearity (GMR%) based on letemovir pharmacokinetic parameters in the pharmacokinetic population

PK Parameter	Day 5 N=14		Day 16 N=14	Accumulation Ratio (Day 16/Day 5)		Time Linearity (Day 16 $AUC_{0-24}$ /Day 5 $AUC_{0-24}$ )	
	$AUC_{0-24}$	$AUC_{inf}$	$AUC_{0-24}$	GMR (90% CI)	Pseudo Within Subject %CV	GMR (90% CI)	Pseudo Within Subject %CV
AUC (hr*ng/mL)	63,056 (51,600, 77,057)	71,128 (58,059, 87,140)	71,482 (55,593, 91,911)	113.4 (90.8, 141.5)	7.26	100.5 (83.8, 120.5)	7.25
$C_{max}$ (ng/mL)	12,918 (10,725, 15,561)	13,018 (10,721, 15,807)	13,018 (10,721, 15,807)	100.8 (79.6, 127.5)	7.71	NA	NA

CI=confidence interval, CV=coefficient of variance, GMR=geometric least-squares mean ratio between treatments (expressed as a percent), SD=single dose, MD=multiple dose.

For Day 5 and Day 16,  $AUC_{0-24}$  and  $AUC_{inf}$  absolute values were back-transformed least-squares mean and 95% CI were from mixed-effects model performed on natural log-transformed values.

Geometric mean ratio (%) and 90% CI were from mixed-effects model performed on natural log-transformed values. Day 16  $AUC_{0-24}$ /Day 5  $AUC_{0-24}$  was used for ratio of AUCs.

Pseudo within-subject %CV =  $100 \cdot \sqrt{(\sigma_e^2 + \sigma_{AB}^2 - 2 \cdot \sigma_{AB})/2}$ , where  $\sigma_e^2$  and  $\sigma_{AB}^2$  are the estimated variances on the log scale for the 2 treatment groups and  $\sigma_{AB}$  is the corresponding estimated covariance, each obtained from the linear mixed-effects model.

## Discussion

### Letemovir Pharmacokinetics

- The estimated GMR and 90% confidence interval for the comparison (letemovir with MMF/letemovir alone) were 1.18 (1.04, 1.32) for letemovir  $AUC_{0-24}$  and 1.11 (0.93, 1.34) for letemovir  $C_{max}$ . The CI for AUC, but not  $C_{max}$ , lay completely above 1, suggesting a small increase in letemovir exposure when dosed with MMF
- Letemovir  $T_{max}$  was about 2 hours whether administered alone or administered with MMF
- The geometric mean linearity ratio (MD  $AUC_{0-24}$ /SD  $AUC_{0-24}$ ) and 90% CI for letemovir were 1.01 (0.84, 1.21), indicating consistency with linear kinetics (Table 4)
- The geometric mean accumulation ratio and 90% CI for letemovir were 1.13 (0.91, 1.42) for  $AUC_{0-24}$  and 1.01 (0.80, 1.28) for  $C_{max}$  (Table 4)

### MPA Pharmacokinetics

- The estimated GMR and 90% confidence interval for the comparison (MMF with letemovir/MMF alone) were 1.08 (0.96, 1.21) for MPA  $AUC_{0-24}$  and 0.96 (0.81, 1.13) for MPA  $C_{max}$ . The GMRs were close to 1 and the confidence intervals included 1, suggesting that coadministration with letemovir had no effect on the single-dose PK of MPA
- Median  $T_{max}$  was the same whether MMF was administered with letemovir or administered alone (0.52 hr), as was terminal half-life (geometric mean ~13 hr)

## Conclusions

- Multiple-dose administration of 480 mg letemovir daily with a single dose of 1 g MMF was generally well tolerated by the healthy subjects in this study
- Coadministration of letemovir and MMF had no clinically meaningful effect on the PK of letemovir or MPA
- Letemovir and MMF may be coadministered without dose adjustment

### Disclosures and Acknowledgements

This research was funded by Merck & Co., Inc., Kenilworth, NJ.

The authors would like to thank:

- All the subjects who participated in this study
- Clinical research unit staff

### Authors declare the following affiliations:

WL Marshall, JR Butterson, C Badshah, F Liu, F Colon-Gonzalez, B Kantesaria, CR Cho, and EE Marcantonio are current employees of Merck & Co., Inc., Kenilworth, NJ.


### Contact Information:

Cyrus Badshah, MD  
c/o William Marshall, MD  
Merck Research Laboratories  
Merck & Co., Inc.  
BMB3-421  
33 Avenue Louis Pasteur  
Boston, MA 02115  
Phone: 617-992-3239  
william.marshall@merck.com

## Subjects and Methods

- This was an open-label, fixed-sequence, single- and multiple-dose trial to characterize the pharmacokinetic interaction between letemovir and MPA in 14 healthy adult females
- Eligible subjects received 1 g oral MMF on Days 1 and 12 and 480 mg oral once-daily letemovir on Day 5 and Days 8-16. Blood samples for pharmacokinetic evaluation (after an 8-hour fast) were collected on Days 1, 5, 12, and 16
- Pharmacokinetic sampling of plasma for MPA and for letemovir was obtained at prespecified time points
- Safety assessments and monitoring were performed throughout the duration of the study

Figure 1. Study Design



Presented at the American Society for Blood and Marrow Transplantation Meetings, February 11-15, 2015, San Diego, California.